



MATINS
HEALTHCARE PVT. LTD.

MATINS HEALTHCARE PVT.LTD.

PLOT No.-10, SECTOR-5, IIE, SIDCUL, HARIDWAR
Mfg.Licence No.: 61/UA/SC/P-2006 & 62/UA/2006

QUALITY CONTROL DEPARTMENT (FINISHED)

(The Drugs & Cosmetics Act 1940 and the Rules there under)

CERTIFICATE OF ANALYSIS

Product Name	Glycitop-MR 30 Tablets	A.R. No.	MFGT-231619
Generic Name	Gliclazide Modified Release Tablets 30 mg	Batch Size	1.0LacTablets
Batch No.	MT-231619	Sample Qty.	100 Tablets
Mfg. Date	12/2023	Sample received date	18/12/2023
Exp. Date	11/2025	Date of Release	19/12/2023
Sr. No.	TESTS	SPECIFICATIONS	RESULTS
1	Description	White colour round shape, biconvex uncoated modified release tablets.	White colour round shape, biconvex uncoated modified release tablets.
2	Identification: By HPLC	The retention time of the major peak in the chromatogram of the sample solution corresponds to that in the chromatogram of the standard solution, as obtained in the assay.	Complies
3	Average weight	200 mg $\pm$ 7.5% (185.0 mg to 215.0 mg)	199.40mg
4	Uniformity of weight	$\pm$ 7.5% on average weight	Positive deviation= 1.45% Negative deviation= 1.36%
5	Dissolution After 1 st hour After 4 th hour After 12 th hour	NMT 20% 20% to 55% NLT80%	(11.15% to 16.18%) (32.56% to 41.15%) (90.13% to 96.23%)
6	Assay: Each uncoated modified release tablet contains:		
	Gliclazide IP 30 mg	Not Less Than 90% and Not More Than 110% (27.0 mg to 33.0 mg)	30.48 mg (101.60%)
Remarks: The product complies as per IP Standard.			
 19/12/2023 Analyzed by  19/12/2023 Checked by  Approved by			